Hikma Pharmaceuticals
OTCMKTS:HKMPYHikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
AXS Cannabis ETF
NYSEARCA:THCXThe Cannabis ETF (THCX) is an exchange-traded fund that is based on the AXS Cannabis index. The fund tracks an index of legal cannabis companies selected and weighted by market capitalization. The fund primarily holds North American companies but may also invest in other countries. THCX was launched on Jul 9, 2019 and is managed by AXS Investments.
